What is Paratus Sciences?
Founded in 2021, Paratus Sciences operates at the intersection of evolutionary biology and artificial intelligence. By leveraging the unique biological adaptations of bats, the company is pioneering a new class of medicines designed to address complex cardiometabolic, immune, and inflammatory diseases. The firm integrates multi-omic data and genomics to identify novel therapeutic targets that have historically remained elusive. This methodology positions Paratus Sciences as a high-growth entity within the biotechnology sector, utilizing computational power to accelerate the transition from biological insight to clinical application.
How much funding has Paratus Sciences raised?
Paratus Sciences has raised a total of $100M across 1 funding round:
Series A
$100M
Series A (2023): $100M with participation from Polaris Partners, ARCH Venture Partners, and ClavystBio
Key Investors in Paratus Sciences
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing deep operational expertise and resources for long-term growth.
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups to commercialize innovations from academic and research institutions.
ClavystBio
ClavystBio is a life sciences venture investor focused on accelerating the development of innovative therapeutics and health technologies by providing strategic capital and operational support.
What's next for Paratus Sciences?
With the recent capital deployment, Paratus Sciences is well-positioned to scale its R&D operations and advance its lead candidates through the preclinical pipeline. The strategic focus will likely remain on refining its AI-driven discovery platform to broaden its therapeutic reach. As the company matures, the emphasis will shift toward establishing clinical partnerships and validating its proprietary targets in human models. This funding round provides the necessary runway to solidify its market position as a leader in nature-inspired drug development, ensuring that the firm can sustain its rigorous scientific inquiry while navigating the complexities of the modern pharmaceutical ecosystem.
See full Paratus Sciences company page
